Search results
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.2% After Analyst Downgrade
ETF DAILY NEWS· 8 hours agoCRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 0.2% during mid-day trading on Friday after Citigroup lowered their price target on the stock from $89.00 to $84.00 ...
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $84.00
ETF DAILY NEWS· 5 hours agoCRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price objective dropped by investment analysts at Citigroup from $89.00 to $84.00 in a research note issued on ...
Mitsubishi UFJ Asset Management Co. Ltd. Has $218,000 Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
ETF DAILY NEWS· 1 day agoMitsubishi UFJ Asset Management Co. Ltd. lowered its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 22.4% during the fourth quarter, according ...
Is CRISPR Therapeutics a Millionaire Maker?
Motley Fool via Yahoo Finance· 3 days agoWith a gene therapy for two illnesses out the door, and with sales slated to take off over the next few quarters, CRISPR Therapeutics (NASDAQ: CRSP) is...
Chutes & Ladders—CRISPR Therapeutics finds new CMO in Sanofi leader
FierceBiotech· 21 hours agoPlease send the good word—or the bad—from your shop to Gabrielle Masson and it will be featured here...
ERS Genomics and IRBM sign CRISPR / Cas9 license agreement
BioPharma-Reporter· 5 days agoCRISPR licensing company ERS Genomics and drug discovery firm IRBM have entered into a non-exclusive...
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
The Motley Fool via AOL· 3 days agoLet's check out these two bull market buys to own for the long run. Image source: Getty Images. 1. ...
The Realities And Ethics Of Pig Organ Transplants In Humans : 1A
NPR· 2 days agoWith CRISPR technology, scientists can edit pig genes to be more compatible with a human body, or at...
Cathie Wood Pulls the Trigger on These 2 ‘Strong Buy’ Stocks
TipRanks via Yahoo Finance· 4 days agoCathie Wood is famous for her singular investing style. Favoring high growth and disruptors, she...
Idorsia’s Jean-Paul Clozel retires as CEO, plots next steps; CRISPR Therapeutics nabs CMO from...
Endpoints News· 23 hours ago→ Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether. Jörn Aldag, Felix Ehrat and Peter Kellogg are stepping ...